Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SZSE:000661'
s Net Margin % Range Over the Past 10 Years
Min: -3.2 Med: 21.63 Max: 35.52
Current: -3.2
SZSE:000661's Net Margin % is ranked worse than 68.75% of 960
companies
in the Drug Manufacturers industry
Industry Median: 5.205
vs SZSE:000661: -3.20
Changchun High-Tech Industry (Group) Co (SZSE:000661) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Changchun High-Tech Industry (Group) Co Net Margin % Related Terms
Changchun High-Tech Industry (Group) Co Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Changchun High-Tech Industry (Group) Co Net Margin % Chart
Changchun High-Tech Industry (Group) Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Changchun High-Tech Industry (Group) Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Changchun High-Tech Industry (Group) Co Net Margin % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Changchun High-Tech Industry (Group) Co (SZSE:000661) has a Net Margin % of 6.75% as of Jun. 2026. Net margin is the ratio of total net income to net sales. View historical data on Changchun High-Tech Industry (Group) Co and its competitors. This is 69% below median its historical median of 21.63. According to the industry distribution chart, Changchun High-Tech Industry (Group) Co ranks #660 out of 960 companies in the Drug Manufacturers industry, placing it in the top 68.7%.
Is Changchun High-Tech Industry (Group) Co's Net Margin % too high?
Changchun High-Tech Industry (Group) Co's current Net Margin % of 6.75% is 69% below median its 10-year median of 21.63. The Drug Manufacturers industry median Net Margin % is 5.21. Changchun High-Tech Industry (Group) Co's value of 6.75% is 29.7% above this industry median. Based on the distribution chart, Changchun High-Tech Industry (Group) Co ranks #660 out of 960 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Changchun High-Tech Industry (Group) Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Changchun High-Tech Industry (Group) Co's Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Changchun High-Tech Industry (Group) Co ranks #660 out of 960 companies for Net Margin %. This places Changchun High-Tech Industry (Group) Co in the lower half of its industry. The industry median Net Margin % is 5.21. Changchun High-Tech Industry (Group) Co's value of 6.75% is 29.7% above this benchmark. While the company's 10-year median is 21.63 vs. the industry median of 5.21, Changchun High-Tech Industry (Group) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.21, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Changchun High-Tech Industry (Group) Co's current Net Margin % of 6.75% is 29.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Changchun High-Tech Industry (Group) Co and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Changchun High-Tech Industry (Group) Co's current Net Margin % is 6.75%, which is 69% below median its own 10-year median of 21.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Changchun High-Tech Industry (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Changchun High-Tech Industry (Group) Co (SZSE:000661) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥85.96, compared to a current price of ¥74.76 — trading 13% below its estimated fair value. The current Net Margin % is 6.75%, which is 69% below median its 10-year median of 21.63 and 29.7% above the Drug Manufacturers industry median of 5.21. Changchun High-Tech Industry (Group) Co's overall GF Score™ is 84/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Changchun High-Tech Industry (Group) Co (SZSE:000661), the current Net Margin % is 6.75% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Changchun High-Tech Industry (Group) Co (SZSE:000661) Overvalued in 2026?
Based on GuruFocus' analysis, Changchun High-Tech Industry (Group) Co stock appears to be undervalued.
The current stock price of ¥74.76 is trading 13% below its estimated GF Value™ of ¥85.96.
GuruFocus considers Changchun High-Tech Industry (Group) Co to be Modestly Undervalued.
Key valuation signals for SZSE:000661:
Net Margin %: 6.75% (69% below median its 10-year median of 21.63)
GF Value™: ¥85.96 vs. price of ¥74.76 (13% below fair value)
Industry Position: 29.7% above the Drug Manufacturers median (#660 of 960)
No single metric tells the full story. See the SZSE:000661 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Changchun High-Tech Industry (Group) Co Ltd is engaged in the production and sales of biopharmaceuticals, Chinese patent medicine production, and real estate development. The company operates its business through three segments. The Pharmaceuticals segment focuses on the research and development, manufacturing, and sales of genetically engineered biologics, human vaccines, traditional Chinese medicines, and chemical pharmaceuticals. The Real Estate segment is involved in property development and sales. The Services segment provides scientific research and technical support, along with leasing and various business-related services. It generates the majority of its revenue from the Pharmaceuticals segment.
84GF Score
Get the complete analysis for SZSE:000661
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:000661 has been successfully added to your 
